| Business Summary | | OXIS
International
Inc.
is
engaged
in
the
discovery,
development
and
commercialization
of
therapeutic
and
diagnostic
products
to
diagnose,
treat
and
prevent
diseases
of
oxidative
stress.
Oxidative
stress
occurs
when
the
concentration
of
free
radicals
and
reactive
oxygen
species
(ROS),
highly
reactive
molecules
produced
during
oxidative
processes,
exceed
the
body's
antioxidant
defense
mechanisms.
The
Company
offers
more
than
140
research
products
for
sale,
which
include
assays
for
markers
of
oxidative
stress,
spin
traps,
antibodies,
proteins,
specialty
chemicals
and
controls.
The
Company's
subsidiary,
OXIS
Instruments,
Inc.,
develops,
manufactures,
markets
and
sells
primarily
medical
instruments
in
its
Pennsylvania
facility. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | OXIS
International
develops,
manufactures
and
markets
selected
therapeutic
and
diagnostic
products
jand
medical
instruments
used
to
diagnose,
treat
and
prevent
diseases
of
oxidative
stress.
For
the
six
months
ended
6/30/01,
revenues
rose
5%
to
$1.8
million.
Net
loss
rose
40%
to
$2.9
million.
Revenues
reflect
higher
sales
of
therapeutic
drug
monitoring
assays
and
research
assays
and
fine
chemicals.
Higher
loss
reflects
the
inclusion
of
write-down
charges. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Joseph Bozman, Jr., 55 Chairman,
Pres, CEO | $68K | -- | Jon Pitcher, 51 CFO,
VP of Fin. and Admin., Sec. | 135K | $57K | Humberto Reyes, 55 Pres,
OXIS Health Products Inc. | 182K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|